Compare ADSK & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADSK | ALNY |
|---|---|---|
| Founded | 1982 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.3B | 42.1B |
| IPO Year | 1994 | 2004 |
| Metric | ADSK | ALNY |
|---|---|---|
| Price | $239.39 | $307.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 29 |
| Target Price | $338.88 | ★ $467.68 |
| AVG Volume (30 Days) | ★ 1.8M | 913.6K |
| Earning Date | 02-26-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.15 | ★ 206.88 |
| EPS | ★ 5.23 | 2.33 |
| Revenue | ★ $7,206,000,000.00 | $1,037,418,000.00 |
| Revenue This Year | $15.10 | $53.50 |
| Revenue Next Year | $10.33 | $32.29 |
| P/E Ratio | ★ $47.35 | $134.28 |
| Revenue Growth | 17.53 | ★ 22.88 |
| 52 Week Low | $215.01 | $205.87 |
| 52 Week High | $329.09 | $495.55 |
| Indicator | ADSK | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 35.87 |
| Support Level | $215.51 | $296.91 |
| Resistance Level | $262.07 | $310.00 |
| Average True Range (ATR) | 6.31 | 9.36 |
| MACD | -0.64 | -0.12 |
| Stochastic Oscillator | 7.68 | 26.55 |
Founded in 1982, Autodesk is a multinational software company best known for pioneering computer-aided design, or CAD, with its AutoCAD product. Nowadays, Autodesk provides design software for a variety of verticals, including architecture & construction, manufacturing, and media & entertainment. Autodesk products have been used in some of the world's most iconic landmarks, like Burj Khalifa, and well-known movie titles like Avatar.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.